Actively Recruiting
Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma
Led by Ruijin Hospital · Updated on 2025-08-11
212
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignant tumors. Although neoadjuvant chemoradiotherapy combined with surgery has significantly improved the survival rate of patients with locally advanced esophageal cancer, approximately half of the patients will experience local regional recurrence or distant metastasis. Lymphocytes are crucial immune cells in the human body, playing a key role in combating infections and tumor development. In recent years, an increasing body of research has indicated that lymphocyte depletion is a significant factor associated with poor prognosis in various solid tumors, including esophageal cancer. The lymphocyte depletion caused by radiotherapy has garnered considerable attention from oncologists. However, there is still a lack of prospective clinical research data on lymphocyte protection in thoracic tumors. Therefore, this study aims to provide high-level evidence from evidence-based medicine regarding the correlation between lymphocyte depletion and prognosis in esophageal cancer patients, offering more effective strategies and methods to improve the outcomes of neoadjuvant chemoradiotherapy for esophageal cancer.
CONDITIONS
Official Title
Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients able to understand and willing to participate, with signed consent
- Pathologically confirmed esophageal squamous cell carcinoma
- Locally advanced ESCC (clinical stage cT3-4 or lymph node positive)
- Age between 18 and 80 years
- Karnofsky Performance Status (KPS) score greater than 80
You will not qualify if you...
- Metastatic esophageal cancer diagnosis
- Refusal to receive systemic drug treatment
- Clinical diagnosis of pleural metastasis or malignant pleural effusion
- Pregnant or breastfeeding women
- Severe non-cancerous medical conditions affecting radiotherapy implementation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin hospital, Shanghai jiaotong university school of medicine
Shanghai, China, China, 200025
Actively Recruiting
Research Team
W
Wei-Xiang Qi, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here